U.S. License Holder:
Date of License:
SIMPONI ARIA (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate;
Active Psoriatic Arthritis (PsA) in patients 2 years of age and older;
Adult patients with active Ankylosing Spondylitis (AS);
Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older.